Accueil   Calls for projects   H2020 Health / Call - Better Health and care, economic growth and sustainable health systems

H2020 Health / Call – Better Health and care, economic growth and sustainable health systems

This call will aim at reconciling better health and healthy ageing with the need to develop sustainable health and care systems and growth opportunities for the health and care related industries.

Key features of the call for projects

Porteur(s) de projet : Académique, Clinique, ETI, Grand groupe, PME

Opening date: November 7th, 2017

Date de clôture : October 2nd, 2018

Dimension : Europe

Funding:

Type de financement : Subvention

Thématique(s) médicale(s) : All

Secteur(s) industriel(s) :

The scope of the call may range from prevention, diagnosis, stratified approaches, predictive toxicology, the development of novel and repurposed therapeutic approaches, including medical technologies and advanced therapies, cohorts and registries-based research, to integration of care and systemic digital solutions for health and ageing well.

It aims to translate new knowledge into innovative applications and accelerate large-scale uptake and deployment in different health and care settings, making health and care systems and services more accessible, responsive and efficient in Europe and beyond.

 

To this end, the inclusion of private companies and other innovators in the projects is encouraged. Research areas to be addressed under this priority will implement and provide the evidence base for global and EU policies mentioned as 'policy drivers in the Introduction'.

 

This call will be implemented through five main priorities:

 

1. Personalised medicine

SC1-BHC-01-2019: Understanding causative mechanisms in co- and multimorbidities (RIA)

Proposals should identify and validate causative mechanisms (e.g. molecular, genetic, correlative, drug-drug interaction) combining mental and physical disorders through the integration of basic, pre-clinical and/or clinical research. Applicants should prove the relevance of the identified mechanisms for co-morbid development. Where pertinent, development of biomarkers and other technologies for diagnosis and monitoring of comorbid conditions in patients is encouraged. A purposeful exploitation of existing data, biobanks, registries and cohorts is expected12, but does not exclude generation of new data. Sex and gender aspects, age, socio-economic, lifestyle and behavioural factors and any other nonhealth related individual attributes should be taken into consideration. SME participation is strongly encouraged.   This call is not open

SC1-BHC-02-2019: Systems approaches for the discovery of combinatorial therapies for complex disorders (RIA)

Research should aim to understand at systems level the pathophysiology of a disorder in groups of patients responding well or poorly to particular therapies and further develop combinatorial therapies tailored to the needs of individuals or stratified patient groups. Projects should focus on already available and/or authorised therapies and have access to standardized biobank samples derived from retrospective or currently running clinical studies. These patient samples should be re-analysed with modern high-throughput technologies. The existing and newly produced data should be integrated using systems approaches, which could combine sub-cellular/cellular and/or organ level in-silico models and network analysis as appropriate, and used to build more sophisticated computational frameworks to predict patient responses to combinatorial therapies. These predictions should be validated in pre-clinical and clinical studies taking into account sex and gender differences. Funding of late stage clinical trials is not within the scope of this topic.   This call is not open

SC1-BHC-03-2018: Exploiting research outcomes and application potential of the human microbiome for personalised prediction, prevention and treatment of disease (RIA)

The aim is to achieve understanding of balanced states of health and on that basis to deliver personalised approaches and clinical tools for predicting and preventing diseases. Proposals should integrate and use high quality microbiome, metabolome and other -omics data produced by large scale international initiatives. They should combine and expand these data with approaches including disease-oriented functional analysis, endogenous and exogenous factors, innovative imaging, functional, structural and lifestyle, ageing, dietary data, environmental data, mental disorders and/or any other comorbidity.   Link to the participant portal

SC1-BHC-04-2018: Rare Disease European Joint Programme Cofund (COFUND-EJP)

The overall objective is to implement a European Joint Programme (EJP) Cofund for Rare Diseases which would create a research and innovation pipeline “from bench to bedside” ensuring rapid translation of research results into clinical applications and uptake in healthcare for the benefit of patients. The initiative should follow the policies and contribute to the objectives of the International Rare Diseases Research Consortium (IRDiRC).   Link to the participant portal

SC1-BHC-05-2018: International flagship collaboration with Canada for human data storage, integration and sharing to enable personalised medicine approaches (RIA)

To build a collaboration of stakeholders in Europe and Canada in the domain of repositories storing and sharing human –omics data that will create a framework for long-term cooperation. In order to do so, this programme aims to enhance and standardise data deposition, curation and exchange procedures thus ensuring better data reuse and increased benefit to the scientific communities worldwide. The selected projects should build on the data quality metrics, standards and access policies developed by major international initiatives.   Link to the participant portal

SC1-HCO-01-2018-2019-2020: Actions in support of the International Consortium for Personalised Medicine (CSA)

Many needs for coordination and support activities have been identified by ICPerMed, which includes representatives from most EU countries along with several other European countries and Canada. Also the wider internationalisation of ICPerMed can be underpinned by coordinating networking activities with third countries. Each action should focus on one of the following fields:

  • International aspect: links with third countries by analysing the potential and advantages of collaboration in personalised medicine with those countries
  • Regional aspect: networking between regions and interregional cooperation in different European countries
  • Healthcare- and pharma-economic models for personalised medicine
  • Standardisation for clinical study design

Link to the participant portal

SC1-HCO-02-2018: Data integration and data-driven in-silico models for enabling personalised medicine - a European standardization framework (CSA)

The proposal should establish a forum for in-silico methodologies applied in translational and clinical research, where different transnational initiatives should meet and debate on their standardisation strategies. The project should evaluate the data integration and data-driven in-silico models strategies and identify best practices for integrating and modelling heterogeneous human disease data transnationally. The project should focus on those heterogeneous types of human data which are best structured (addressing relevant ethical implications and sex and gender differences) and thus pose fewer technical challenges for transnational sharing of data.   Link to the participant portal

SC1-HCO-04-2018: ERA-NET to support the Joint Programming in Neurodegenerative Diseases strategic plan

Proposals should pool the necessary financial resources from participating national or regional research programmes in the area of neurodegenerative diseases research by implementing a transnational joint call for proposals resulting in grants to third parties with EU co-funding, with a view to scale-up the implementation of the JPND Research Strategy. Proposers are requested to also implement other joint activities, including training and additional joint calls without EU co-funding. Link to the participant portal

2. Innovative health and care industry

SC1-BHC-07-2019: Regenerative medicine: from new insights to new applications (RIA)

Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function. Projects should focus on innovative translational research to develop regenerative processes towards the ultimate clinical goal of addressing unmet clinical needs of large patient groups. Proposals should be based on new approaches such as genome editing or gene therapy, transdifferentiation or in vivo reprogramming, cell therapy and transplantation, 3D bioprinting, organoids or use of combined products (non-exhaustive list for illustrative purposes only).   This call is not open

SC1-BHC-09-2018: Innovation platforms for advanced therapies of the future (RIA)

Building on European strengths and using the definition set out in Regulation (EC) 1394/2007, projects should create knowledge, testing and exploitation platforms around innovative concepts for advanced therapy development. Platforms should comprise the components and expertise necessary to create a solid foundation on which to build possible new therapeutic approaches and/or aim to overcome particular development bottlenecks. Possible components could include studying the basic biology of the potential therapy and investigating its mode of action, proof of concept (in vitro, in animal models – where necessary – or first-in–man studies); safety, efficacy, characterisation, refinement and manufacturing of the product could be considered.   Link to the participant portal

SC1-BHC-10-2019: Innovation Procurement: Next generation sequencing for routine diagnosis (PCP)

The objective is to implement NGS in routine diagnostics for personalised medicine and scale up demand-driven innovation for healthcare systems. This includes organisational, economical, technical and clinical aspects. It should lead to NGS tests, clinically validated procedures (including sex analysis), quality assurance schemes, tools and methods for data collection, management, analysis and interpretation, with a view to assist clinical decisionmaking and foster medical research and innovation.   This call is not open

SC1-HCO-05-2018: Strengthening regulatory sciences and supporting regulatory scientific advice (CSA)

Proposals should; (i) establish, regularly update and disseminate a comprehensive inventory 43 of existing support activities for regulatory Scientific Advice and Protocol Assistance in Europe such as the Innovation Task Force briefing meetings; (ii) analyse the effectiveness of existing support activities and develop a common strategy for training programmes to strengthen regulatory sciences and improve support for successful outcomes from regulatory Scientific Advice and Protocol Assistance based on identified best practices; (iii) support and/or advice for the delivery of corresponding pilot training programmes in an efficient and collaborative manner, and (iv) assess the need for and possibly propose additional mechanisms sustainably supporting academic groups in regulatory Scientific Advice and Protocol Assistance procedures.   Link to the participant portal

3. Infectious diseases and improving global health

SC1-BHC-13-2019: Mining big data for early detection of infectious disease threats driven by climate change and other factors (RIA)

It is expected that proposals develop: 1. the technology to allow the pooling, access, analysis and sharing of relevant data, including next generation sequencing; 2. the innovative bio-informatics and modelling methodologies that enable risk modelling and mapping; and 3. the analytical tools for early warning, risk assessment and monitoring of (re-)emerging infectious disease threats.   This call is not open

SC1-BHC-14-2019: Stratified host-directed approaches to improve prevention, treatment and/or cure of infectious diseases (RIA)

Proposals should test emerging concepts in drug and/or vaccine development in order to address the problem of antimicrobial drug resistance and to optimize therapeutic, curative or preventive measures against infectious diseases of major concern for Europe. Proposals should capitalize on knowledge of the role of host factors, immune-modulators or of hostpathogen interactions influencing disease outcome that can be utilized to strengthen the response to treatment or prevention measures. This should lead to new enhanced therapies, cures and/or preventive measures.   This call is not open

SC1-BHC-15-2018: New anti-infective agents for prevention and/or treatment of neglected infectious diseases (RIA) - 06 Feb 2018 (First Stage) / 04 Sep 2018 (Second Stage)

IMPORTANT NOTE : Deadlines for this call in two stage: 06 Feb 2018 (First Stage) / 04 Sep 2018 (Second Stage)     The topic bridges the gap between preclinical and early clinical development of drugs and/or vaccines against neglected bacterial and parasitic diseases56. Therefore, the proposed actions should focus on late preclinical (e.g. validation in animal models, toxicology, Good Manufacturing Practices (GMP) production, preparation of Investigational Medicinal Product Dossier) and early clinical (up to phase 1) development of already existing lead drug and vaccine candidates. Multidisciplinary platforms bringing together academic and industry research teams, from European and disease-endemic countries, with the capacity to exploit existing experience and propose innovative solutions addressing several relevant pathogens are particularly encouraged.   Link to the participant portal

SC1-BHC-16-2018: Global Alliance for Chronic Diseases - Scaling-up of evidence-based health interventions at population level for the prevention and management of hypertension and/or diabetes (RIA)

Proposals must focus on the scale-up of interventions at population level for hypertension and/or diabetes prevention and/or management in LMIC, and/or in vulnerable populations in HIC. Proposals addressing comorbidities with either hypertension or diabetes, including between them, are encouraged.   Link to the participant portal

SC1-BHC-18-2018: Translational collaborative cancer research between Europe and the Community of Latin American and Caribbean States (RIA)

Proposals must focus on translational and multidisciplinary research to identify specific patient groups in view of improving one or more of the following aspects: screening, early detection, diagnosis, and/or prognosis. Proposals must build on the diverse genetic backgrounds, risk factors, cancer incidence , geographical environment, and/or different healthcare models (including social care and volunteers) in European and CELAC countries. Proposals may integrate molecular, behavioural, nutritional, clinical, social and environmental epidemiology data from cohorts; registries; biobanks; repositories; research infrastructures…   Link to the participant portal

SC1-BHC-19-2019: Implementation research for maternal and child health (RIA)

Proposals should focus on implementation research for improving maternal and child health with a focus on the first ‘1000 days’ from pregnancy until two years of age. This research can take place in either high income countries or low and middle income countries, or in a combination thereof.   This call is not open

SC1-BHC-21-2018: Research on HIV, tuberculosis (TB) and/or hepatitis C (HCV) in patients with mono-, co-infections and/or comorbidities in the context of fostering collaboration with the Russian Federation (RIA)

Proposals should address one or more of the following subtopics: 1. TB: To investigate biomarkers or new diagnostic tests for early screening of TB risk groups for TB infection and identification of antimicrobial drug resistance. 2. HIV: To investigate the susceptibility to HIV and/or disease progression rate after infection, including various HIV subtypes and/or transmission clusters, and/or the development of adverse effects during antiretroviral therapy and concomitant diseases (comorbidities and/or co-infections, including with tuberculosis). 3. HCV: To evaluate the genetic determinants of the virus and the host, and comorbid conditions that can be involved in disease progression and create the basis for the development of future HCV treatment strategies.   Link to the participant portal

SC1-HCO-06-2018: Establishment of an International Network of Social Sciences Research Centres to help address governance and other challenges in the preparedness for and the response to infectious threats (CSA)

The scope of this Coordination and Support Action (CSA) is to: I. Initiate, in an organised and coordinated manner, the International Network of Social Sciences Research Expertise, addressing governance challenges, engage with stakeholders on behalf of network members, and work with research funding agencies to grow the network to an effective, internationally representative scale. II. Establish the central coordinating hub for the network under development, focusing on maximising opportunities for collaboration, learning and data sharing in order to scale-up evidence.   Link to the participant portal

SC1-HCO-08-2018: Creation of a European wide sustainable clinical research network for infectious diseases (CSA)

Proposals should build on successful European collaborative initiatives such as PREPARE and COMBACTE and further advance clinical research in the field of infectious disease by supporting the establishment of a European wide multidisciplinary clinical research network. Such a network should be capable of performing all clinical trial aspects encompassing study design, execution and reporting (sex and gender differences analysis to be included where relevant). It should develop and allow for innovative research approaches and enable flexibility in responding to unpredictable events and signals. The network should provide clear and direct access for stakeholders including academic organizations, SMEs and larger industry to perform clinical studies.   Link to the participant portal

SC1-HCO-09-2018: Building international efforts on population and patient cohorts (CSA)

Building on existing cohorts and in close alliance with relevant research infrastructures, proposals should establish a strategy for the development of the next generation of integrated cohorts, including: 1. Map the cohort landscape in Europe and large international initiatives. The mapping should include, for instance meta-data on purpose, coverage and measurements and any other relevant information. 2. Identify best strategies for cohorts’ integration, taking into account relevant ethical issues. 3. Promote the harmonisation of past and future data collection and provide recommendations on standards to improve future sample and data collection. 4. Etc.   Link to the participant portal

SC1-HCO-10-2018: Coordinating European brain research and developing global initiatives (CSA)

Proposals should: 1. Identify areas of neurosciences where the need for enhanced coordination of research communities into active clusters is particularly acute; 2. Accelerate exchange between researchers in different European research initiatives to promote cooperation and to minimise fragmentation and duplication; 3. Support the emergence of these clusters, facilitate links with research infrastructures and other major initiatives, in coordination with European Commission services, with the aim of sharing data and enhancing the exploitation of results, fostering new collaborations and identifying future research objectives; 4. Etc.   Link to the participant portal

SC1-HCO-11-2018: Strategic collaboration in health research and innovation between EU and China (CSA)

The objective of this action is to support networking between European and Chinese policy makers, programme owners and funders, with the following goals: 1. To develop a sustainable platform between EU and China that will facilitate a constant dialogue on addressing common health R&I challenges. 2. To identify health challenges, whose solution may benefit from closer bi-lateral and/or multi-lateral cooperation between EU and China, to facilitate and develop collaborative research initiatives between EU and Chinese stakeholders.   Link to the participant portal

4. Innovative health and care systems - Integration of care

SC1-BHC-22-2019: Mental health in the workplace (RIA)

Proposals should develop and implement intervention(s) that an employer/organization can take to promote good mental health and prevent mental illness in the workplace. These interventions can be newly developed or improvements on existing ones. They should address challenges in mental health in the workplace in the EU. The interventions should be assessed in terms of direct and indirect individual and collective health outcomes and costeffectiveness, implementation facilitators and barriers.   This call is not open

SC1-BHC-23-2018: Novel patient-centred approaches for survivorship, palliation and/or end-of-life care (RIA)

Proposals should demonstrate, the effectiveness and cost-effectiveness of new, improved or specifically adapted pharmacological and/or non-pharmacological interventions to either relieve symptoms (e.g. pain) and suffering caused by life-threatening noncommunicable diseases (including disabilities), or serious late and long-term side effects of disease treatments in patients and survivors, or symptoms that occur at the end of life.   Link to the participant portal

SC1-BHC-25-2019: Demonstration pilots for implementation of personalised medicine in healthcare (IA)

The pilot projects should demonstrate the benefit for individuals as well as the implementability and economic viability of personalised medicine approaches in real life healthcare settings. The pilots should be tailored to the needs of citizens, making use of a wide variety of data and proposing prediction, prevention or treatment solutions, focussing on diseases with high burden to society (taking due account of sex/gender differences) and including multi-morbidity conditions if relevant. The use of big data approaches and high performance computing is encouraged.   This call is not open   Planned opening date: 26 July 2018

SC1-BHC-26-2018: HTA research to support evidence-based healthcare (RIA)

Proposals should develop new or improved methodological approaches and frameworks, and foster methodological consensus-building, to address all of the following areas: 1. Specific types or groups of health technologies 2. Selected therapeutic areas 3. Use of real-world data 4. Implementation. The proposed consortium should bring together partners with relevant expertise from e.g. academia, HTA bodies, regulators, centres of expertise for clinical research and care, scientific and medical learned societies, and organisations involved in developing evidencebased clinical guidelines and systematic reviews in healthcare.   Link to the participant portal

SC1-HCO-12-2018: Innovation in healthcare - a CSA towards using pre-commercial procurement and public procurement of innovative solutions in healthcare systems (CSA)

The objective of this coordination and support action (CSA) is to create a Europe-wide consortium of healthcare providers and public procurers in the health and social care sector that define together unmet procurement needs to implement innovative solutions in healthcare.   Link to the participant portal

5. Decoding the role of the environment, including climate change, for health and wellbeing

SC1-BHC-27-2018: New testing and screening methods to identify endocrine disrupting chemicals (RIA)

New and improved approaches are needed to increase the quality, the efficiency and the effectiveness of existing methods to meet demanding and evolving regulatory requirements worldwide. In consultation with relevant regulatory bodies, research should improve and harmonise screening and testing protocols/strategies and hazard/risk assessments by developing better and faster tools, test methods or models, including in vitro and in vivo tests, high-throughput and in silico methods (e.g. QSAR), potentially combined with research on adverse outcomes pathways. For in vitro tests, appropriate coupling of their results to human health effects should be ensured.  Link to the participant portal

SC1-BHC-28-2019: The Human Exposome Project: a toolbox for assessing and addressing the impact of environment on health (RIA)

Applicants should take advantage of the last decade’s rapid technological advances which have opened up new opportunities to collect, combine and analyse large data sets offering new possibilities to understand the contribution of environmental factors to the global health burden of common chronic diseases. Proposals should use innovative approaches to the systematic and agnostic identification of the most important environmental risk factors for the development of major NCDs across the life course (including in utero), leading to preventive interventions at the individual, group or population level and contribute to sustainable healthcare.   This call is not open

SC1-HCO-13-2018: Setting the priorities for a European environment, climate and health research agenda (CSA)

The aim is to establish a research/policy coordination group consisting of relevant science and policy actors in environment and health from H2020-funded activities and national/EU regulatory bodies as well as relevant international actors. The objective is to identify proactively key policy areas requiring scientific support for environment, climate change and health related issues in the next decade and develop a European medium-term research and innovation strategy and agenda.   Link to the participant portal

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree